As per the reports published by Market Research Future (MRFR), the worldwide ulcerative colitis market has been recorded as a growing market. The market can be estimated to generate remarkable worth in the coming future. Ulcerative colitis is a category of inflammatory bowel disease (IBD) that mostly impacts the lower region of the body such as the rectum and sigmoid colon. Diarrhea, bleeding from the rectum, belly pain, and cramps are some of the common signs of ulcerative colitis market. As per the studies conducted by the Centers for Disease Control, global prevalence of ulcerative colitis market Research Report has been recorded to be witnessing 0.5 to 24.5 cases per 100,000 people every year. Chances of recurrence of the ailment’s signs is also high. The Colitis Foundation of America stated that almost 30% of people on remission are likely to suffer from the ailment seethe in the future, right after the cure and remission.

Ulcerative Colitis Market Size was valued at USD 7.2 billion in 2022. The Ulcerative Colitis market industry is projected to grow from USD 7.5744 Billion in 2023 to USD 10.26697 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.20% during the forecast period (2023 - 2030). 

Key Players 

Global ulcerative colitis market has been dominated by key players such as AbbVie Inc., Allergan, Inc., UCB S.A., Pfizer Inc., Takeda Pharmaceutical Company Limited, Ferring B.V., Bayer AG, Perrigo Company plc,  Janssen Biotech, Merck, and Johnson Johnson Services, Inc.

Regional Analysis

In 2016, North America was projected to account for the largest share of the worldwide ulcerative colitis market followed by Europe. The region is likely to continue dominating the pack over the forecast period. In the Asia-Pacific region, China leads the ulcerative colitis market. Improvement of healthcare facilities coupled with economic development are accelerating the development of the market.

Market Segmentation

Global ulcerative colitis market outlook has been segmented based on medication and type. Based on medication the market has been segmented into steroids, 5-aminosalicylates, immunomodulators, biologics, and purine analogs. Biologics are estimated to hold the largest market share. Steroids drugs are likely to expand at the highest CAGR over the forecast period. Based on types, the market has been segmented as proctosigmoiditis, ulcerative proctitis, research ulcerative colitis, pancolitis or universal colitis, fulminant colitis, and left-sided colitis. Ulcerative proctitis has been estimated to hold the largest market share over the forecast period.

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013,

United States of America